Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This study aims to determine effectiveness of Gefitinib (Iressa) in recurrent glioblastoma
after standard treatment (surgery, radiationtherapy and at least a first line chemotherapy).
Gefitinib is a specific inhibitor of the epidermal growth factor receptor (EGFR). EGFR is
elevated in more than 50% of malignant gliomas. At recurrence, secondary surgery and pre- and
postoperative Gefitinib is offered to patients in good performance status. Clinical outcome
of patients and correlation to translational research will be evaluated.